Israel’s Teva Pharmaceutical Industries (NYSE: TEVA) today announced the exclusivelaunch of a generic version of Reyataz (atazanavir) capsules in the USA.
Atazanavir sulfate capsules are a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection for patients six years and older weighing at least 15kg.
US pharma major Bristol-Myers Squibb's (NYSE: BMY) Reyataz had annual sales of around $402 million in the USA, according to IMS data as of October 2017 quoted by Teva.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze